GRAIL, Inc. Common Stock — 四半期決算報告書 (NASDAQ:GRAL)

チャート全体を表示

Financials

概要明細書統計

期次年次

Market Capitalization 2.1589 B
Employee 910
Founded 2015
CEO N/A
Website www.grail.com
Headquarter Delaware, United States
FIGI BBG01N6CGW43
Industry 診断・研究

総売上高

当期純利益

1株当たり基本利益（基本EPS）

有利子負債合計

フリーキャッシュフロー

現金および現金同等物

2.16 B 時価総額

株価収益率

-7.7

売上高対価格比率

21.37

GRAIL Inc

GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021. In June 2021 GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.